In conclusion, we developed a recombinant adenovirus vector, Ad-CD44-N-HIF3α4, containing a synNotch receptor gene which inhibited CD44 signaling and hypoxia-induced response in cancer cells. This evidence concerns the gene CD44 and cancer.